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Abstract
It has been known for some time that human autoimmune diseases can be triggered by viral
infections. Several possible mechanisms of interactions between a virus and immune system
have been analysed, with a prevailing opinion being that the onset of autoimmunity can in many
cases be attributed to ”molecular mimicry”, where linear peptide epitopes, processed from viral
proteins, mimic normal host self proteins, thus leading to a cross-reaction of immune response
against virus with host cells. In this paper we present a mathematical model for the dynamics
of an immune response to a viral infection and autoimmunity, which takes into account T cells
with different activation thresholds. We show how the infection can be cleared by the immune
system, as well as how it can lead to a chronic infection or recurrent infection with relapses and
remissions. Numerical simulations of the model are performed to illustrate various dynamical
regimes, as well as to analyse the potential impact of treatment of autoimmune disease in the
chronic and recurrent states. The results provide good qualitative agreement with available data
on immune responses to viral infections and progression of autoimmune diseases.
1 Introduction
A successful immune system relies on its ability to discriminate between cells infected with a
pathogen such as virus and the uninfected cells of the host. The breakdown in discrimination of
self-antigens results in autoimmunity, where the immune system attacks specific cells or organs.
The specificity of the immune response focuses disease within different target organs, for example,
pancreatic β-cells in insulin-dependent diabetes mellitus type-1 (IDDM), the central nervous system
in multiple sclerosis (MS), or the retina in uveitis - an inflammation of the eye [44, 42, 25].
Multiple factors are known to contribute toward the onset and development of autoimmune
diseases, including genetic predisposition, age, and environment. Amongst the environmental fac-
tors, the major identified triggers of autoimmunity are believed to be infectious pathogens [6, 9].
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Experimentally, direct infection of islet cells in the pancreas led to bystander damage of the islet
cells and autoimmunity, and it was concluded that the release of sequestered antigen was critical to
the development of disease [22]. There is also a strong association between infection with hepatitis
C and autoimmune hepatitis [32]. While it is certainly not the case that all autoimmune disease is
triggered by infection of the organ that subsequently becomes the target, this is a reasonable model
for several known examples of organ specific autoimmunity.
There are many mechanisms by which host infection by a pathogen may contribute to autoimmu-
nity, including triggering the innate immune system, molecular mimicry and bystander activation
(see, e.g., [16] for a recent review). Molecular mimicry is thought to be particularly important
when viruses cause autoimmunity [16, 17, 33, 51]. An immune response elicited against a viral
protein that mimics a self antigen will not only eliminate the virus, but can also target normal host
cells that display the cross-reactive self-antigen. Such interactions may play a role both in causing
disease and also in precipitating a relapse of disease. Between such triggering events, disease can
of remit in part because of the existence of regulatory pathways that dampen immune responses.
Whilst significant advances have been made in mathematical modelling of various aspects of
general virus dynamics and the interactions between viruses and the immune system of the host,
theoretical studies of autoimmunity have been quite limited in comparison. One of the earliest
mathematical models of autoimmunity did not explicitly include specific causes of autoimmunity
but rather concentrated on the interactions between effector and regulator cells, and used this to
get an insight into T cell vaccination [46]. Further progress in the context of T cell vaccination
was made by Borghans et al. [7, 8], who demonstrated how the interactions of autoreactive and
regulatory T cells can lead to the onset of autoimmunity or stable oscillations around a vaccinated
state. Burroughs et al. [10] have studied the onset of autoimmunity through bystander activation.
Wodarz and Jansen [52] analysed autoimmunity in the context of viral causes of cancer. They
included viral infections indirectly through an increased rate of uptake of self-antigen by antigen-
presenting cells. Leo´n et al. [28, 29, 30] have studied the dynamics of interactions between different
T cells for the purposes of regulation of immune response and control of autoimmune reaction. More
recently, Iwami et al. [23, 24] derived and studied a model for autoimmunity, which makes explicit
account of the virus dynamics and its interaction with the immune system by means of linear or
nonlinear immune response. Despite its simplicity, this model appears unable to reproduce a normal
clearance of virus during a single infection, as it does not allow for a viral expansion. Various roles
played by the regulatory T cells in the dynamics of autoimmunity have recently been analysed by
Alexander & Wahl [2].
There are several ways to account for the ability of T cells to discriminate between cells pre-
senting self antigens and infected cells. One of these is through regulatory cells, which are triggered
by autoantigens and inhibit the activity of autoreactive T cells. This approach has already been
extensively used in models of immune response, see Alexander & Wahl [2], Burroughs et al. [10]
etc. Another approach is to consider T cells, which can perform a wide range of immune function
by virtue of having different or tunable activation thresholds (TAT). This concept has been defined
previously as: ”activation is a threshold phenomenon and the threshold is tuned by the stimula-
tory experience of the cell” [18], i.e. T cells continually tune their responsiveness to T cell antigen
receptor (TCR) stimulation through stimuli evoked by autoantigens. Because the degree of au-
toreactivity of T cells is continuously controlled through their activation and tuning, this approach
provides another way of modelling the onset and development of autoimmune disease. Grossman
and Paul [18, 20], and Grossman and Singer [19] developed models with tunable activation thresh-
olds that were applied to peripheral and to central T cell activation. Altan-Bonnet and Germain
have modelled signalling threshold and shown differences in activation/response threshold that are
dependent on the activation state of the T cell [1]. Noest [37] has shown how the need for activa-
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tion threshold tuning arises from the first principles of signal detection theory, see also Scherer et
al. [45] for further discussion of this issue. van den Berg and Rand have studied mathematically
two cellular response models of the dynamics of tunable activation threshold [49]. Carneiro et al.
[11] have performed a comparative study of two mechanisms of self-tolerance: tuning of activation
thresholds and control by specific regulatory T cells. The authors have shown that these two mech-
anisms are complementary and together provide a plausible explanation of the observed dynamics
of immune tolerance. Besides purely theoretical studies, dynamical changes in T cell activation
during their circulation have also been shown experimentally both in the mouse and in man, where
it has important implications for the outcome of specific therapeutic interventions [5, 36, 43, 48].
In this paper we propose and study a mathematical model for autoimmune disease caused
by viral infections through molecular mimicry. By introducing separate populations of regular
activated T-cells and T-cells with a lower activation threshold to self-antigen which arises as a result
of the infection, the model is able to qualitatively reproduce normal aspects of immune behaviour.
The model presented in this paper differs from an earlier work in this particular modelling aspect,
as well as in the explicit account for a viral infection represented both by infected cells, and by a
separate population of free virions.
The organization of this paper is as follows. In the next section we discuss various biological
assumptions behind the origins of autoimmunity and derive the corresponding mathematical model.
In Section 3 we perform a systematic analysis of the steady states of the model and their stability.
Section 4 contains results of numerical simulations in different parameter regimes, which illustrate
clearance of infection, onset of autoimmunity, periodic flare-ups, as well as the dynamics of multiple
infections. The paper concludes with the discussion of obtained results in Section 5.
2 The model
We are interested in modelling the interactions between a viral infection and a human host immune
system, that lead to the onset of autoimmunity through molecular mimicry. When cells in a
particular organ of the body become infected with a pathogen, the elicited immune response may
cross-react with one or more self-antigens that share determinants with the pathogen [51]. This
subsequently can lead to a breakdown of tolerance for self antigens through the appearance of
lymphocytes capable of attacking the host’s own cells, both in the same and in other organs. For
both viral and bacterial pathogens, there is evidence that their antigens derived from pathogens
engage and expand both CD4 and CD8 T cells that drive autoimmune disease [12, 40]. Furthermore,
recent genetic studies of autoimmunity implicate many genes that control T cell expansion and
activation threshold [14]. Hence, it is important to understand a model of autoimmune disease
that specifically addresses the dynamics of T cells. While it is unarguable that antibodies are
important in many types of autoimmune disease, there is good evidence that T cell recognition
of antigenic peptides is often a critical initiating step. For example, in a model of rheumatoid
arthritis, antibodies were sufficient to induce disease [27] but the development of antibodies depends
on prior T cell interactions with bacteria [55]. Furthermore, in some of the experimental models
of autoimmunity, B cells are dispensable, and disease develops when they are not present [54].
Therefore, the balance of evidence is for a necessary T cell component in the onset and development
of autoimmunity, and our model specifically seeks to address this.
To model the dynamics of an immune response during a viral infection and possible onset
of autoimmunity, we employ a model similar to those studied earlier in the context of immune
responses [38, 52]. Let A denote the number of susceptible cells in a particular organ or tissue.
We consider two distinct populations of susceptible cells, A1 and A2 to allow for a situation when
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autoimmunity takes place in a different organ to the one where the original infection occurs. It
is assumed that in the absence of infection or autoimmunity, these two cell populations would be
maintained at a certain constant level supported by homeostasis. It has been previously shown
[23, 24] that a specific form of the growth function for susceptible cells can have a significant effect
on the overall dynamics of autoimmune diseases, and here we use the logistic form, as studied in
Iwami et al. [23], and by Perelson and Nelson [41] in models for HIV infection.
When a person acquires a viral infection, a proportion of cells become infected with this virus,
and after a certain period of time the infected cells, whose population is denoted by F , will start
producing virions (free virus particles) V that will go on to infect other as yet uninfected cells A2
(and, possibly, A1). All time constants, such as the time to encounter an uninfected cell and a time
required for cell entry, are implicitly included in the rate of infection λ. In the absence of infection,
the na¨ıve T-cells Tin are taken to follow a logistic growth. Once activated, Tin cells become T1
cells that have the ability to kill infected cells F . For a fraction of these cells T2 their activation
threshold for stimulation by susceptible cells that are not infected is reduced, allowing them to kill
A cells. This is the autoimmune response. It has already been shown that T cells with varying
activation threshold can have a significant effect on the dynamics of the immune response [18, 19].
With the above assumptions, the model to be analysed in this paper has the form
dA1
dt
= r1A1
(
1−
A1
N1
)
− p1λA1V − αaT2A1,
dA2
dt
= r2A2
(
1−
A2
N2
)
− λA2V − p2αaT2A2,
dF
dt
= λ(p1A1 +A2)V − µFF − αFT1F − αaT2F,
dTin
dt
= gtTin
(
1−
Tin
M
)
− αactTinF,
dT1
dt
= αactTinF − T1(µ1 + τ),
dT2
dt
= τT1 − µ2T2,
dV
dt
= kF − γV,
(1)
where A1,2, F , Tin, T1, T2 and V denote the populations of susceptible cells (possibly, affected by
infection and autoimmunity separately), infected cells, na¨ıve T cells, activated T cells, T cells with
a lower activation threshold to self-antigen, and free virus, respectively. As it has already been
mentioned, in the absence of infection which can trigger autoimmune reaction, the susceptible cells
A1,2 reproduce logistically with their respective linear growth rates r1,2 and carrying capacities
N1,2. These cells become infected at a rate λ, and they are destroyed at a rate αa by autoreactive
T-cells T2 with a lower activation threshold to self-antigen (this is the actual implementation of the
autoimmunity mechanism). Na¨ıve T-cells Tin are assumed to have a logistic growth with a linear
growth rate gt and a carrying capacity M ; they get primed by dendritic cells at a rate taken to be
proportional to the number of infected cells with a constant αact.
Once infected, cells presenting foreign antigen F die at a rate µF , and they are also destroyed
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by the activated T-cells T1 at a rate αF , and by the autoreactive T-cells T2 at a rate αa. Activated
T-cells T1 die at a rate µ1, and at a rate τ they produce autoreactive T cells T2 with a lower
activation threshold to self-antigen. Finally, the T cells T2 die at a rate µ2. Free virions V are
produced by an infected cell at a rate k, and γ is the natural clearance rate of the virus.
Parameters 0 ≤ p1, p2 ≤ 1 control whether the populations of susceptible cells are affected
by autoimmune reaction and/or infection. When p1 = p2 = 0, only cells A2 are affected by the
infection, and the autoimmunity only affects the population A1 of other cells. Biologically, this
situation arises when a pathogen causes infection in one part of the body, and the autoimmune
response causes damage in other parts of the body. If p1 = 0 and p2 > 0, only the cell population
A2 experiences infection, but both of the susceptible cell populations are affected by the developing
autoimmunity. Conversely, if p2 = 0 and p1 > 0, both A1 and A2 cells become infected, and only
A1 also experiences autoimmunity. Finally, in the case of p1,2 > 0, both of the cell populations
A1 and A2 get exposed to both the infection and the autoimmune reaction, although they can
potentially be affected by infection/autoimmunity at different rates, and the differences in intrinsic
growth rates and carrying capacities of these two cell populations can also lead to a significantly
different dynamics of these two cell populations.
The main emphasis of the above model is on the separation of T cell populations into two
activated populations, one of which is capable of an autoimmune reaction through having a lower
activation threshold to self-antigen. As we are particularly interested in the role of foreign infections
in the onset of autoimmunity, we have not explicitly included in the model several other aspects that
can be of interest in specific contexts, such as antibody response or regulatory T cells. Furthermore,
we have not included memory cells in our model, which can be important in the analysis of a longer-
term dynamics or multiple infections.
3 Steady states
We begin our analysis of the system (1) by considering its steady states E∗ = (A∗
1
, A∗
2
, F ∗, T ∗in, T
∗
1
, T ∗
2
, V ∗),
which can be found by equating the right-hand side of system (1) to zero. Stability is determined
by the eigenvalues of the Jacobian of linearization of the system (1) near each of the steady states.
In order to systematically study the steady states of system (1), we first consider all steady states
with V ∗ = 0 (this immediately implies F ∗ = T ∗
1
= T ∗
2
= 0). There are exactly eight of such steady
states:
E∗
1
= (0, 0, 0, 0, 0, 0, 0), E∗
5
= (N1, 0, 0, 0, 0, 0, 0),
E∗
2
= (0, 0, 0,M, 0, 0, 0), E∗
6
= (N1, 0, 0,M, 0, 0, 0),
E∗
3
= (0, N2, 0, 0, 0, 0, 0), E
∗
7
= (N1, N2, 0, 0, 0, 0, 0),
E∗
4
= (0, N2, 0,M, 0, 0, 0), E
∗
8
= (N1, N2, 0,M, 0, 0, 0).
(2)
Computing the Jacobian at each of these steady states shows that E∗
1
to E∗
7
are always saddles
(and hence unstable) for any values of the system parameters. The steady state E∗
8
is a stable
node, provided
kλ(N2 + p1N1) < µFγ,
or a saddle if
kλ(N2 + p1N1) > µFγ.
At
kλ(N2 + p1N1) = µFγ,
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the steady state E∗
8
undergoes a steady state bifurcation, where one of the eigenvalues goes through
zero along the real axis. Biologically, the above stability condition represents the rate of change in
the number of infected cells being negative at the steady state.
When V ∗ 6= 0, we can have either A∗
1
= 0 and A∗
2
6= 0, or A∗
1
6= 0 and A∗
2
= 0, or A∗
1
6= 0 and
A2 6= 0. In the case where A
∗
1
= 0 and A∗
2
6= 0, there are two options. One of these is E∗
9
with
T ∗in = T
∗
1
= T ∗
2
= 0, in which case we also have
A∗2 =
µFγ
λk
, F ∗ =
r2γ
λk
(
1−
µFγ
λkN2
)
, V ∗ =
r2
λ
(
1−
µFγ
λkN2
)
.
The steady state E∗
9
with such values of the variables is stable, provided the following conditions
are satisfied
p1r2N2λk > λkr1N2 + p1r2γµF , αactr2γλkN2 > gtλ
2k2N2 + αactr2γ
2µF ,
γµF r2(µF + γ) + λkN2[(µF + γ)
2 + µFγ − λkN2] > 0.
(3)
It is noteworthy that when p1 = 0, this steady state is unstable for any values of other parameters.
For p1 = 1, this steady state can only be stable, provided the linear growth rate r2 sufficiently
exceeds r1. The steady state E
∗
9
can undergo a steady state bifurcation when
p1r2N2λk = λkr1N2 + p1r2γµF , or αactr2γλkN2 = gtλ
2k2N2 + αactr2γ
2µF , (4)
and it can also undergo a Hopf bifurcation, when the system parameters satisfy the conditions
p1r2N2λk > λkr1N2 + p1r2γµF , αactr2γλkN2 > gtλ
2k2N2 + αactr2γ
2µF ,
γµF r2(µF + γ) + λkN2[(µF + γ)
2 + µFγ − λkN2] = 0.
(5)
An important observation is that the manifold A1 = Tin = T1 = T2 = 0 is flow-invariant, and
the Hopf bifurcation of the steady state E∗
9
takes place inside this manifold, which results in the
appearance of a periodic orbit confined to the same manifold. The importance of this observation
lies in the fact that this periodic solution does not cause oscillations of any of the variables which
would go below zero, making it unrealistic.
The second option for the case A∗
1
= 0 and A∗
2
6= 0 is given by the steady state E∗
10
, for which
T ∗in satisfies the quadratic equation
gtγαact[r2γ(αFµ2 + αaτ) + p2αaτN2λk](T
∗
in)
2
−gt[r2γ
2αactM(αFµ2 + αaτ)− λ
2k2N2µ2(µ1 + τ) + p2λτγαaαactkMN2]T
∗
in
+µ2M(µ1 + τ)[r2γαact(N2λk − µFγ)− λ
2k2gtN2] = 0,
(6)
and the other variables are given by
A∗2 =
γ
λk
[
µF +
αFµ2 + αaτ
µ2(µ1 + τ)
gtT
∗
in
(
1−
T ∗in
M
)]
,
F ∗ =
gt
αact
(
1−
T ∗in
M
)
, V ∗ =
kgt
γαact
(
1−
T ∗in
M
)
,
T ∗1 =
gt
µ1 + τ
T ∗in
(
1−
T ∗in
M
)
, T ∗2 =
τgt
µ2(µ1 + τ)
T ∗in
(
1−
T ∗in
M
)
.
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Depending on the particular values of parameters there can be between zero and two distinct steady
states determined by the roots of equation (6). It does not prove possible to determine stability
of the steady state E∗
10
in a closed form, and hence one has to compute the eigenvalues of the
corresponding Jacobian numerically.
In a similar way, when A∗
1
6= 0 and A∗
2
= 0, there are again two options. The first one, denoted
by E∗
11
, describes the case when T ∗in = T
∗
1
= T ∗
2
= 0, and the other variables can be found as
A∗1 =
µFγ
λp1k
, F ∗ =
r1γ
λp1k
(
1−
µFγ
λp1kN1
)
, V ∗ =
r1
λp1
(
1−
µFγ
λp1kN1
)
.
The steady state E∗
11
is stable, provided the following conditions are satisfied
p1λkr1N1 > p
2
1
λkr2N1 + r1γµF , αactp1r1γλkN1 > p
2
1
gtλ
2k2N1 + αactr1γ
2µF ,
γµF r1(µF + γ) + p1λkN1[(µF + γ)
2 + µF γ − p1λkN1] > 0.
(7)
The steady state E∗
11
can undergo a steady state bifurcation when
p1λkr1N1 = p
2
1λkr2N1 + r1γµF , or αactp1r1γλkN1 = p
2
1gtλ
2k2N1 + αactr1γ
2µF , (8)
and it can also undergo a Hopf bifurcation, when the system parameters satisfy the conditions
p1λkr1N1 > p
2
1
λkr2N1 + r1γµF , αactp1r1γλkN1 > p
2
1
gtλ
2k2N1 + αactr1γ
2µF ,
γµF r1(µF + γ) + p1λkN1[(µF + γ)
2 + µF γ − p1λkN1] = 0.
(9)
Similarly to the case of E∗
9
, the Hopf bifurcation of the steady state E∗
11
takes place inside the
flow-invariant manifold A2 = Tin = T1 = T2 = 0. Analogously to the analysis of stability of the
steady state E9, one can note that for stability of the steady state E11, the linear growth rate r1
should be sufficiently greater than the rate r2.
The second option for the case A∗
1
6= 0 and A∗
2
= 0 is E∗
12
, for which T ∗in is different from zero
and satisfies the quadratic equation
gtγαact[r1γ(αFµ2 + αaτ) + p1αaτN1λk](T
∗
in)
2
−gt[r1γ
2αactM(αFµ2 + αaτ)− p
2
1
λ2k2N1µ2(µ1 + τ) + p1λτγαaαactkMN1]T
∗
in
+µ2M(µ1 + τ)[r1γαact(p1N1λk − µF γ)− p1λ
2k2gtN1] = 0,
(10)
with the other variables being given by
A∗1 =
γ
p1λk
[
µF +
αFµ2 + αaτ
µ2(µ1 + τ)
gtT
∗
in
(
1−
T ∗in
M
)]
,
F ∗ =
gt
αact
(
1−
T ∗in
M
)
, V ∗ =
kgt
γαact
(
1−
T ∗in
M
)
,
T ∗1 =
gt
µ1 + τ
T ∗in
(
1−
T ∗in
M
)
, T ∗2 =
τgt
µ2(µ1 + τ)
T ∗in
(
1−
T ∗in
M
)
.
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Finally, when both A∗
1
6= 0 and A∗
2
6= 0, there are again two options. The first one corresponds
to a steady state E∗
13
with T ∗in = T
∗
1
= T ∗
2
= 0, and the other variables being given by
F ∗ =
r1r2γ [(p1N1 +N2)λk − µFγ]
λ2k2(r1N2 + p21r2N1)
, V ∗ =
r1r2 [(p1N1 +N2)λk − µF γ]
λ2k(r1N2 + p21r2N1)
,
A∗1 =
N1[λkN2(r1 − p1r2) + µFγr2p1]
λk(r1N2 + p21r2N1)
, A∗2 =
N2[λkp1N1(p1r2 − r1) + µFγr1]
λk(r1N2 + p21r2N1)
.
Numerical computation of the eigenvalues of linearization shows that for sufficiently small values
of γ, the steady state E∗
13
is stable; as γ increases, stability is lost, but then regained again as γ
increases further still.
The final possibility corresponds to a steady state E∗
14
with the values of all variables being
different from zero, so that T ∗in satisfies the quadratic equation
gtγαact [λαaτk(p1r2N1 + p2r1N2) + γr1r2(αFµ2 + αaτ)] (T
∗
in)
2
−gt
{
Mγαact[λkαaτ(p1r2N1 + p2r1N2) + γr1r2(αFµ2 + αaτ)]
−λ2k2µ2(µ1 + τ)(p
2
1
r2N1 + r1N2)
}
T ∗in − µ2M(µ1 + τ)[λ
2k2gt(p
2
1
r2N1 + r1N2)
−λkγαactr1r2(p1N1 +N2) + µF γ
2αactr1r2] = 0,
(11)
and the other variables can be found as
A∗1 =
N1 [µ2M(µ1 + τ)(r1γαact − p1λkgt) + γαaαactτgtTin(T
∗
in −M)]
Mµ2γαactr1(µ1 + τ)
,
A∗2 =
N2 [µ2(µ1 + τ)(r2γαactM + λkgt(T
∗
in −M)) + p2γαaαactτgtT
∗
in(T
∗
in −M)]
Mµ2γαactr2(µ1 + τ)
,
F ∗ =
gt
αact
(
1−
T ∗in
M
)
, V ∗ =
kgt
γαact
(
1−
T ∗in
M
)
,
T ∗1 =
gt
µ1 + τ
T ∗in
(
1−
T ∗in
M
)
, T ∗2 =
τgt
µ2(µ1 + τ)
T ∗in
(
1−
T ∗in
M
)
.
To illustrate how stability of different steady states is affected by the system parameters, we
show in Fig. 1 regions in the k-λ parameter plane where different steady states are stable depending
on whether infection and autoimmunity affect the same of different cell populations. This figure
suggests that for sufficiently small rate of infection λ, the only possible stable steady state is the
disease-free state E∗
8
, in which cell populations A1, A2 and Tin are maintained at their respective
carrying capacities, and there no free virus or infection, thus implying the absence of activated T
cells T1 and T2. As the infection rate λ increases, this disease-free steady state loses stability, and
the system turns to a stable state of chronic infection E14, where all cell populations are different
from zero. When this steady states loses stability in the case of p1 = p2 = 1 (i.e. when both cell
populations A1 and A2 are the targets of both infection and autoimmunity), there appear to be no
other stable steady state for any values of λ and k, as illustrated in plot 1(a). At the same time, it
is worth noting that some other stable steady states can be recovered when other parameters are
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Figure 1: Stability regions of different steady states depending on λ and k. Parameter values are
r1 = 0.2, r2 = 0.1, N1 = 200, N2 = 300, M = 300, gt = 0.2, αF = 0.0006, αact = 0.04, αa = 0.033,
µF = 1, µ1 = 0.08, µ2 = 0.02, τ = 0.001. (a) p1 = p2 = 1. (b) p1 = p2 = 0. Colour code denotes
region of stability of a single steady state: E∗
8
(violet), E∗
14
(green), E∗
13
(red), E∗
10
(blue), and white
denotes a parameter region where all steady states are unstable.
changed. For instance, stability of the steady states E9 and E11 depends heavily on the relation
between the two linear growth rates r1 and r2, so varying these may produce additional stable
steady states. In the case p1 = p2 = 0, the range of possibilities is much wider, as shown in plot
1(b). It is possible to observe stable state E10, where the cell population A1 is equal to zero with
all other populations being positive. Another possibility is a state E13, in which infection renders
virus specific T cells ineffective. An important observation is that in all parameter regimes there
appears to be a single stable steady state, hence no bi-stability is possible in the system. Whilst
Figure 1 may not illustrate the complete catalogue of possible steady states, it provides an insight
into how stability is affected by the system parameters.
We summarize the above analysis of possible steady states of the system (1) in the following
table.
9
Disease-free
steady states
V = F = 0,
Tin = T1 = T2 = 0
E1
all cell populations are equal to zero,
always unstable
E2
Tin =M , all other populations are
equal to zero, always unstable
E3
A2 = N2, all other populations are
equal to zero, always unstable
E4
A2 = N2, Tin =M , all other populations
are equal to zero, always unstable
E5
A1 = N1, all other populations are
equal to zero, always unstable
E6
A1 = N1, Tin =M , all other populations
are equal to zero, always unstable
E7
A1 = N1, A2 = N2, all other populations
are equal to zero, always unstable
E8
A1 = N1, A2 = N2, Tin =M , all other
populations are equal to zero, can be
stable or unstable
Steady states
with a chronic
viral infection
V > 0
E9
A1 = Tin = T1 = T2 = 0, other
populations are positive, can be
stable or unstable
E10
A1 = 0, all other populations are
positive, can be stable or unstable
E11
A2 = Tin = T1 = T2 = 0, other
populations are positive, can be
stable or unstable
E12
A2 = 0, all other populations are
positive, can be stable or unstable
E13
Tin = T1 = T2 = 0, other populations
are positive, can be stable or unstable
E14
all cell populations are positive,
can be stable or unstable
4 Numerical simulations
In order to illustrate various dynamical regimes that can be exhibited our model, we solve the the
system (1) numerically in different parameter regimes, taking account of results concerning stability
and bifurcations of the steady states analysed in the previous section. Prior to performing simula-
tions, we simplify the system by introducing the non-dimensional variables (Â1, Â2, F̂ , T̂in, T̂1, T̂2, Â1, V̂ )
and t̂ as follows,
t̂ = gtt, A1 = N1Â1, A2 = N2Â2, F = (N1 +N2)F̂ ,
Tin =MT̂in, T1 =MT̂1, T2 =MT̂2, V = V0V̂ .
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Substituting these variables into the system (1) yields
dÂ1
dt̂
= r̂1Â1
(
1− Â1
)
− p1λ̂Â1V̂ − α̂aT̂2Â1,
dÂ2
dt
= r̂2Â2
(
1− Â2
)
− λ̂Â2V̂ − p2α̂aT̂2Â2,
dF̂
dt
= λ̂
[
p1NpÂ1 + (1−Np)Â2
]
V̂ − (µ̂F + α̂F T̂1 + α̂aT̂2)F̂ ,
dT̂in
dt̂
= T̂in
(
1− T̂in
)
− α̂actT̂inF̂ ,
dT̂1
dt̂
= α̂actT̂inF̂ − T̂1(µ̂1 + τ̂),
dT̂2
dt̂
= τ̂ T̂1 − µ̂2T̂2,
dV̂
dt̂
= k̂F̂ − γ̂V̂ ,
(12)
where the modified parameters are given by
r̂1 =
r1
gt
, r̂2 =
r2
gt
, λ̂ =
λV0
gt
, γ̂ =
γ
gt
, k̂ =
k(N1 +N2)
gtV0
,
α̂a =
αaM
gt
, α̂F =
αFM
gt
, α̂act =
αact(N1 +N2)
gt
, τ̂ =
τ
gt
,
µ̂1 =
µ1
gt
, µ̂2 =
µ2
gt
, µ̂F =
µF
gt
,
and we have introduced one additional parameter
Np =
N1
N1 +N2
.
The above non-dimensionalization reduces the number of free parameters by three, thus reducing
the overall complexity and simplifying the survey of parameter space. To simplify the notation, we
will drop hats for variables and parameters in the system (12). The values of system parameters
used in simulations of system (12) are the rescaled values of the parameters used in Fig. 1.
4.1 Single infection
First, we consider the situation when the host experiences a single infection by a virus, and one
is interested in the subsequent dynamics of the immune response against this infection, as well as
possible autoimmune reaction. Following Wodarz et al. [52, 53] and Vickers et al. [50], we define a
certain threshold value, below which the infection is considered extinct; for simulations presented
below this threshold was chosen to be 10−8 and applied to the number of infected cells F . Initial con-
dition was taken to be (A1(0), A2(0), F (0), Tin(0), T1(0), T2(0), V (0)) = (0.9, 0.0333, 0, 0.9, 0, 0, 0.05)
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Figure 2: Numerical solution of the system (12) for p1 = p2 = 1. Parameter values are r1 = 1,
r2 = 0.5, Np = 0.4, gt = 0.2, αa = 50, µF = 5, αact = 100, αF = 1, µ1 = 0.4, µ2 = 0.1, τ = 0.005,
k = 105, γ = 10. (a) and (b) λ = 0.1, (c) and (d) λ = 0.5, (e) and (f) λ = 1, (g) and (h) λ = 3. In
all plots, the colours denote infected cells F (blue), activated T cells T1 (red), and autoreactive T
cells T2 (black). Time is measured in arbitrary units (a.u.).
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for all simulations, representing the fact that before the infection there are no infected cells and no
activated T cells.
Figure 2 shows the dynamics of system (12) for the case p1 = p2 = 1, which corresponds to
a situation when both types of cells A1 and A2 are targets of both infection and autoimmunity.
For sufficiently small values of infection rate λ, the infection is being completely cleared: after the
initial peak, the number of infected cells is monotonically decreasing, and the system approaches a
stable steady state E∗
8
, as shown in plots (a) and (b). This is the case of a normal disease clearance,
where immune response of the host is able to completely clear the infection without causing an
autoimmune reaction. Due to the exhaustion of the pool of infected cells, the activation of na¨ıve T
cells stops, and the population of activated T cells is then slowly diminishing. The same happens to
autoreactive T cells, whose number reaches its peak slightly later than the population of activated
T cells, as these cells have to be derived from the population of regular activated T cells T1. It
is worth noting that unlike an earlier model of Iwami et al. [23, 24], the present model is able to
support the initial viral expansion and subsequent clearance of infection by the immune system.
For higher values of λ, the disease-free state E∗
8
loses stability, and the system evolves to a
stable equilibrium E∗
14
, which describes the state of chronic infection. In this case, the immune
system of the host is unable to clear the infection, and as a result it persists at a constant level. As
λ increases further, the steady state E∗
14
loses stability via Hopf bifurcation, giving rise to stable
periodic oscillations, as shown in plots (e) and (f). In this case, one observes episodes of high
viral production (relapses) with long periods of quiescence (remissions). Such dynamics have been
observed in a number of autoimmune diseases, such as MS, autoimmune thyroid disease, uveitis etc.
[4, 15, 39]. An important note here is that none of the subsequent reactivations of the virus requires
any exogenous factors, but rather the system itself cycles through periods of relative quiescence
and viral release. During each viral episode, the number of infected cells increases, and this triggers
rapid activation of na¨ıve T cells, which in turn suppresses viral production, leading to a decrease
in the number of infected cells. As the autoreactive T cells in the simulation shown in Fig. 2 have
a much longer lifetime, their number decreases much more slowly during the periods of relative
suppression of infection. For even higher values of λ, this periodic solution becomes unstable, and
instead the system evolves into another periodic orbit arising from the Hopf bifurcation of the
steady state E∗
12
, in which case the second population of target cells A2 goes to zero.
Next, we consider another biologically plausible scenario when cells A2 are only targeted by
infection, and cells A1 are only affected by autoimmunity, which is described by p1 = p2 = 0.
Figure 3 illustrates the dynamics of the system (12) in this case. For sufficiently small values of
λ, one observes normal clearance of infection similar to the case p1 = p2 = 1, and as λ increases,
the system tends to a stable state of constant chronic infection E∗
14
, as shown in plots (a) and (b).
When the steady state E∗
14
loses stability, rather than develop sustained oscillations as in the case
p1 = p2 = 1, now the system goes instead to a stable steady state E
∗
13
shown in plots (c) and (d),
which has Tin = T1 = T2 = 0. This situation describes a state, in which the numbers of na¨ıve,
activated and autoreactive T cells are all zero. While this is not biologically realistic, functionally
it resembles exhaustion in which virus specific T cells are rendered ineffective and therefore the
effective population size is reduced to zero. For higher values of λ, there is another stability switch,
and the system evolves toward a stable equilibrium E∗
10
. This behaviour is shown in plots (e) and
(f), and it describes a situation when the first population of target cells A1 goes to zero. When
λ is increased further still, the steady state E∗
10
becomes unstable, and one observes a state of
autoimmunity represented by stable periodic solution arising from a Hopf bifurcation of a chronic
steady state E∗
14
.
In the case when only one of p1 and p2 is different from zero, the system can exhibit behaviours
similar to the cases described above, with transitions between stable steady states and periodic
13
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Figure 3: Numerical solution of the system (12). Parameter values are the same as in Fig. 2, except
for p1 = p2 = 0. (a) and (b) λ = 0.9, (c) and (d) λ = 1.5, (e) and (f) λ = 5, (g) and (h) λ = 9. In
all plots, the colours denote infected cells F (blue), activated T cells T1 (red), and autoreactive T
cells T2 (black). Time is measured in arbitrary units (a.u.).
14
Figure 4: Numerical solution of the system (12). Parameter values are the same as in Fig. 2, except
for p1 = p2 = 0. (a) and (b) λ = 0.2, (c) and (d) λ = 1. In all plots, the colours denote infected
cells F (blue), activated T cells T1 (red), and autoreactive T cells T2 (black). Time is measured in
arbitrary units (a.u.).
solutions of different origins. Numerical simulations suggest that in most cases, for sufficiently
large values of the infection rate λ, the system approaches a stable periodic orbit arising from the
Hopf bifurcation of the steady state E∗
14
. Such periodic solution corresponds to the above-mentioned
state of autoimmunity with remissions and relapses.
4.2 Multiple infections
Since for many viral infections it is realistic to expect subsequent exposures of a person to the
same virus, we now consider a scenario where someone who has recovered from a primary infection
or currently has a chronic viral infection experiences a secondary viral challenge with the same
virus. It is known that the timing of secondary infection plays an important role in determining
the progress of infection, as well as the immune dynamics [34, 47].
Figure 4 illustrates the dynamics during a secondary viral exposure in the parameter regime
with normal clearance of infection and during the chronic infection. In the case of normal clearance
shown in plots (a) and (b), one can observe that due to a much slower decay of activated T cells, they
still remain at a non-negligible level following the primary infection. This means that the second
infection produces a significantly smaller number of infected cells. The later a secondary viral
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challenge occurs, the higher will be the resulting number of infected cells, and correspondingly the
higher will be the numbers of activated and autoreactive T cells during a secondary infection. We
find that the number of T2 cells during a secondary infection is often higher than during a primary
infection, such that the exacerbation of the autoimmune reaction is relatively much greater than
the antiviral response, as shown in plot (b). The actual level of T1 and T2 cells depend on the timing
of secondary infection: if a secondary infection takes place sufficiently close in time to the original
infection, the number of T1 cells will only increase by a very small amount, while the number of
T2 cells will exceed that number during the primary infection. If, however, a greater time elapses
between the two infections, the number of activated T cells T1 will be slightly greater, but still it
will never exceed the number of T1 cells during a primary episode. At the same time, the number
of cross-reactive T cells T2 in this case will be lower than during the primary infection.
Plots (c) and (d) show that when the system is chronically infected, due to the significant
amount of activated T cells, the secondary infection does not lead to a major increase in the
number of infected cells, and as a result the infection is quickly cleared to the same chronic level
as before the secondary infection. We have also analysed the influence of secondary exposures on
the dynamics of recurrent infections, and in this case the effect of subsequent viral challenges is
quite small in that it does not change the amplitude or period of oscillations except producing a
small additional peak in the number of infected cells immediately after the infection. From this we
conclude that in the parameter regime when the infection is recurrent, the main role is played by
the periodic nature of the system itself, and it is this that causes relapses and remissions, rather
than subsequent infections.
4.3 Treatment
As a next step in the analysis of onset and dynamics of autoimmunity, it is instructive to consider
a practically important issue of therapeutic intervention. Numerical simulations presented earlier
suggest that in the case when autoimmunity is triggered by infection with a virus, there is no
further need for infection to maintain the periodic state of relapses and remissions. Let us now
consider how the autoimmune dynamics changes upon the introduction of a therapy, aimed at
reducing the number of autoreactive T cells. It will be assumed that such treatment can have two
potential impacts: it can either act by eliminating the autoreactive T cells, thereby reducing the
overall burden of autoimmunity, or it can transform those autoreactive T cells into cells with a
higher activation threshold, i.e. activated T cells. These scenarios correspond loosely to treatments
with therapeutic monoclonal antibodies that delete populations of cells [13], or with drugs such as
cyclosporin that inhibit the activation of T cells [31]. In clinical studies, these therapies cannot
yet be made to selectively target autoreactive cells, which remains an important ongoing goal
of treatment. Mathematically, we model such an intervention by modifying the fifth and sixth
equations of the system (1) (and, correspondingly, (12)) as follows
dT1
dt
= αactTinF − T1(µ1 + τ) + p3CT2θ(t− t0),
dT2
dt
= τT1 − µ2T2 − CT2θ(t− t0),
(13)
where C is the rate at which autoreactive T2 cells are destroyed by treatment, p3 shows the fraction
of autoreactive T cells that can be converted into activated T cells (when p3 = 0, the treatment
is only responsible for reducing the number of T2 cells), θ(·) is the Heaviside function, and t0 is
the time when the treatment is introduced. We assume that initially a person is exposed to a viral
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Figure 5: Temporal dynamics during treatment of an autoimmune state. Parameter values are the
same as in Fig. 2, and p3 = 0. (a) and (b) p1 = p2 = 0, λ = 10, C = 30; (c) and (d) p1 = 1, p2 = 0,
λ = 0.65, C = 2; (e) and (f) p1 = 0, p2 = 1, λ = 0.9, C = 2. Time is measured in arbitrary units
(a.u.).
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Figure 6: Temporal dynamics during treatment of a chronic infection. Parameter values are the
same as in Fig. 2, p1 = p2 = p3 = 0, λ = 1, and C = 30. Time is measured in arbitrary units (a.u.).
infection and develops some sort of autoimmune response, and in response to this a treatment is
introduced in order to reduce or eliminate autoimmunity.
Figure 5 shows the effects of treatment on the dynamics of immune response in the regime, where
before treatment the system exhibited sustained periodic oscillations corresponding to relapses and
remission during autoimmunity. All the simulations were performed for the case p3 = 0, but it
has been checked that the same results are obtained for p3 > 0. In the case when p1 = p2 = 0
(i.e. cells A2 are the only target of infection, and cells A1 are only affected by autoimmunity), once
the treatment is introduced, the number of autoreactive T cells reduces significantly, as shown in
plots (a) and (b). Although the oscillations persist after treatment, the number of A1 is greatly
increased, and for sufficiently high rate of treatment C, it stays very close to 1. For p1 = 1 and
p2 = 0 (infection targets both A1 and A2 cells, but only A1 cells are affected by autoimmune
response), plots (c) and (d) indicate that the introduction of treatment leads to a stable steady
state E∗
13
, in which all T cells (Tin, T1 and T2) are eliminated. It is noteworthy that whilst the
autoimmune reaction is eliminated in this scenario, this also leads to an increased level of persistent
infection. When p1 = 0 and p2 = 1 (only A2 cells are a target of infection, and both A1 and A2 cells
are affected by autoimmunity), treatment leads to suppression of oscillations and establishment of
a stable chronic state E∗
14
, as illustrated in plots (e) and (f). Due to a high rate αa, at which
autoreactive T cells T2 destroy infected cells, once the population of these cells is reduced, the
resulting chronic state E14 s characterized by a higher level of infected cells. In the case when
p1 = p2 = 1, behaviour of the system under treatment is qualitatively similar to the case of p1 = 1
and p2 = 0, when all T cells are eliminated.
In Fig. 6 we illustrate how treatment affects the dynamics in the case of chronic infection. One
can observe that treatment leads to a significant reduction in the number of autoreactive T cells,
prompting a substantial increase in the number of A1 cells. However, treatment does not completely
eliminate the infection which remains chronic, and similarly to the treatment of an autoimmune
state, while the treatment reduces the level of autoimmune reaction, it simultaneously leads to a
relative increase in the number of infected cells. This is biologically reasonable since inhibiting
autoimmunity can lead to the reactivation of infection [21].
18
5 Discussion
In this paper we have developed and analysed a mathematical model for the dynamics of the immune
response against a viral infection and the associated onset of autoimmunity. Having introduced
separate populations of target cells that can be affected by infection and/or autoimmunity, as
well as different compartments for T cells with different activation thresholds, we have studied
how the outcome of the immune response can be the clearance of infection, chronic infection or
recurrent infection. In the case of normal clearance, there are no lasting immune consequences
for the organism. The number of autoimmune T cells is small and decreases with time after the
clearance of infection. Chronic infections are characterized by a constant level of activated and
autoreactive immune cells, which keep infection in check but do not clear it. Another possible
scenario for persistent infection is when virus specific T cells is exhausted, and hence the effective
T cell population is reduced to zero. Recurrent infections are characterized by inability of the
immune response to clear an infection, which results in relatively long periods of remission followed
by relapses with a substantial viral production and a large number of cells being infected. In this
study we have focussed on chronic infection driven by an increase in the infection rate λ. Studies in
other models show that chronicity can also be influenced by other factors such as the frequency of
antigen specific T cells [35]. During recurrent infection we observe higher numbers of autoimmune
cells (compared to the case of chronic infection), which exacerbate the relapses and cause more
damage. Notably, there is a difference in the outcome of the infection, depending on whether
infection and autoimmunity affect the same or different organs.
Numerical solutions reveal a number of potentially important features in the dynamics of the
autoreactive cells. When a person experiences a secondary challenge with the same virus, the
model shows that in the case of normal clearance the number of cells getting infected is smaller
in subsequent infections due to a limited number of T cells remaining activated at the time of
secondary infection. Although in this case the infection is still successfully cleared, in a number
of circumstances the second and subsequent peaks in autoreactive cell numbers exceeded that seen
during the initial response to virus (Fig. 4 (b)), thus causing an additional immune challenge.
This could implicate repeated cycles of T cell expansion, or multiple linked rounds of infection as
crucially underpinning the development of frank autoimmune disease. This would be consistent
with multi-hit models of autoimmunity (e.g. [3]) and also with circumstances in which more than
one infectious episode is necessary to precipitate frank disease. In contrast, secondary infection
during a chronic infection does not have a significant effect on the dynamics. The same conclusion
holds for the recurrent infections, thus indicating that in this case it is the intrinsic dynamics of the
interactions between the immune system and the virus that causes remissions and relapses rather
than the fact that a person experiences further infections.
In the form of the model where the population of infected cells is different from that which is the
target of autoimmunity, we found that under some conditions, low levels of viral persistence could
be associated with high levels of autoreactivity (Fig. 3 (e)&(f)). We also demonstrated that the
system can approach a state that resembles T cell exhaustion (Fig. 3 (c)&(d)). This is intriguing
because inactivation of the immune response in the face of chronic viral infection and in tumours
is a well described and important area of ongoing investigation [26].
We have also studied the effects of treatment aimed at reducing the number of autoreactive
cells on the dynamics of the immune response. In the case of the recurrent autoimmune state,
when infection and autoimmunity occur in different organs, such treatment leads to a substantial
improvement of the situation, significantly reducing the number of autoreactive T cells. It is impor-
tant to note that although this does not eliminate episodes of relapses/remissions, they have a much
less prominent impact on the numbers of susceptible cells and hence cause significantly less damage
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than the full-blown autoimmunity. When only one of the susceptible cell populations is the target
of infection but both of them can be affected by autoimmunity, introduction of treatment leads
to suppression of relapse/remission oscillations and establishment of a state of chronic infection.
When initially the infection is chronic, treatment does not qualitatively change the dynamic state
of the system, but leads to a reduction in the number of autoreactive T cells. One should note,
however, that due to reliance of immune system on autoreactive T cells to contribute to control of
infection, any treatment aimed solely at reducing the number of these cells can inadvertently lead
to a higher level of persistent chronic infection. This trade-off between the ability to control the
infection and at the same time to minimize the undesired effects of autoimmunity is somewhat sim-
ilar to the problem in chemotherapy where an effective treatment of a tumor may have a negative
impact on the overall immune status, thus requiring some sort of adjuvant therapy. At the same
time, if the role played by autoreactive T cells in the clearance of infection is not so significant, the
above problem becomes less serious, and it is possible to achieve efficient control of autoimmunity
without compromising host’s ability to fight infection.
There are a number of interesting potential extensions to this work which may be possible in the
future. While we started with the concept of tunable activation thresholds, the implementation we
chose here was deliberately simplified to ensure the tractability of the model. Previous theoretical
and experimental work [1, 2, 18, 19, 20, 49] has stressed the dynamic nature of the tuning process
which can be observed over timescales of minutes to days [43, 48]. It would therefore be interesting
to explore the dynamics of this process and the effects that different parameters for the kinetics of
tuning might have on the development of autoreactive T cell populations. Another feature of the
current model is that the autoimmune response does not persist when the virus is cleared. Since
there is good experimental evidence that autoimmune responses can be self-sustaining and chronic
[25], developing the model to explore this behaviour will be an important further development of
the model.
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